Search results for "Nigrostriatal pathway"

showing 4 items of 4 documents

Improved technique for stereotactic placement of nerve grafts between two locations inside the rat brain

2008

Peripheral nerve grafts have shown the ability to facilitate central axonal growth and regenerate the adult central nervous system. However, the detailed description of a technique for atraumatic graft placement within the brain is lacking. We present a stereotactic procedure to implant a peripheral nerve graft within a rat's brain with minimal brain tissue damage. The procedure permits a correct graft placement joining two chosen points, and the survival and integration of the graft in the host tissue with a light glial reaction, with evidence of central axonal growth inside the graft, at least up to 8 weeks after its implantation. (C) 2008 Elsevier B.V. All rights reserved.

Central nervous systemNigrostriatal pathwayPeripheral nerve graftHost tissueStereotaxic TechniquesMicroscopy Electron TransmissionPeripheral nervemedicineAnimalsRegenerationNigrostriatal pathwaybusiness.industryGeneral NeuroscienceRegeneration (biology)Peripheral nerve graftsBrainAnatomyRat brainSciatic NerveNerve RegenerationRatssurgical procedures operativemedicine.anatomical_structureGrafting stereotactic cannulaStereotactic placementImplantbusiness
researchProduct

Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats

2000

Abstract The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with l -DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic l -DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic l -DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity ma…

Malemedicine.medical_specialtyLevodopaanimal structuresTyrosine 3-MonooxygenaseReceptors DrugDopamine Agents-DOPANigrostriatal pathwayStriatumBiologySubthalamic nucleusStriatumLevodopaLesionAdrenergic AgentsDopamineInternal medicinemedicineAnimalsRNA MessengerRats WistarOxidopamineReceptors CannabinoidMedial forebrain bundleHydroxydopamineTyrosine hydroxylaseGeneral NeuroscienceMedial Forebrain BundleParkinson DiseaseCorpus StriatumRatsmedicine.anatomical_structureEndocrinologynervous systemSettore BIO/14 - Farmacologiamedicine.symptomCannabinoid CB1 receptor mRNA6-Hydroxydopaminemedicine.drugNeuroscience Letters
researchProduct

In Vivo Microdialysis in Parkinson’s Research

2009

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopamine (DA) neurons in the nigrostriatal system, which in turn produces profound neurochemical changes within the basal ganglia, representing the neural substrate for parkinsonian motor symptoms. The pathogenesis of the disease is still not completely understood, but environmental and genetic factors are thought to play important roles. Research into the pathogenesis and the development of new therapeutic intervention strategies that will slow or stop the progression of the disease in human has rapidly advanced by the use of neurotoxins that specifically target DA ne…

MicrodialysisParkinson's diseaseMPTPNigrostriatal pathwayBiologymedicine.diseasechemistry.chemical_compoundmedicine.anatomical_structureNeurochemicalchemistryIn vivoDopamineBasal gangliamedicineNeurosciencemedicine.drug
researchProduct

Nitric Oxide Modulation of the Dopaminergic Nigrostriatal System: Focus on Nicotine Action

2009

Nitric oxide (NO) signalling plays an important role in the integration of information processed by the basal ganglia nuclei. Accordingly, considerable evidence has emerged indicating a role for NO in pathophysiological conditions such as Parkinson’s disease (PD), schizophrenia and drug addiction. To further investigate the NO modulation of dopaminergic function in the basal ganglia circuitry, in this study we used in vivo electrophysiology and microdialysis in freely-moving rats. Pharmacological manipulation of the NO system did not cause any significant changes either in the basal firing rate and bursting activity of the dopamine (DA) neurons in the substantia nigra pars compacta (SNc) or…

Nicotine addictionPars compactaChemistryDopamineDopaminergicNitric oxideSubstantia nigraStriatumSettore BIO/09 - FisiologiaNicotineGlobus pallidusnitric oxideDopaminebasal gangliaBasal gangliamedicinenigrostriatal pathwayNeurosciencedopaminergicnicotinemedicine.drug
researchProduct